Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Hegerova LT, Leal AD, Grendahl DC, Seisler DK, Sorgatz KM, Anderson KJ, Hilger CR, Loprinzi CL. An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy. Support Care Cancer 2015;23:55-9. [PMID: 24964876 DOI: 10.1007/s00520-014-2326-9] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2014] [Accepted: 06/16/2014] [Indexed: 10/25/2022]

For:	Hegerova LT, Leal AD, Grendahl DC, Seisler DK, Sorgatz KM, Anderson KJ, Hilger CR, Loprinzi CL. An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy. Support Care Cancer 2015;23:55-9. [PMID: 24964876 DOI: 10.1007/s00520-014-2326-9] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2014] [Accepted: 06/16/2014] [Indexed: 10/25/2022]

Number

Cited by Other Article(s)

Matsumoto K, Ryushima Y, Sato J, Aizawa Y, Aoyama T, Akaishi Y, Okamoto R, Sato Y, Sugano K, Tazumi K, Tsuji M, Fujikawa N, Bun S, Yagasaki K. Extravasation associated with cancer drug therapy: multidisciplinary guideline of the Japanese Society of Cancer Nursing, Japanese Society of Medical Oncology, and Japanese Society of Pharmaceutical Oncology. ESMO Open 2024;9:103932. [PMID: 39389005 PMCID: PMC11490930 DOI: 10.1016/j.esmoop.2024.103932] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2024] [Revised: 09/08/2024] [Accepted: 09/09/2024] [Indexed: 10/12/2024] Open

Abstract

BACKGROUND

Extravasation (EV), or the leakage of anticancer drugs into perivascular and subcutaneous tissues during intravenous administration, can cause serious conditions that may require surgical intervention. Therefore, updated guidelines for EV based on systematic review are needed. Additionally, classifications for anticancer drugs that cause EV are not standardized across the current guidelines, and some novel drugs have not been classified. Therefore, this study aimed to formulate guidelines using evidence-based information for shared decision making on prevention, early detection, treatment, and care for EV in Japan and provide additional classification for tissue injury based on systematic review.

MATERIALS AND METHODS

The members of the Japanese Society of Cancer Nursing (JSCN), Japanese Society of Medical Oncology (JSMO), and Japanese Society of Pharmaceutical Oncology (JASPO) were surveyed about significant clinical challenges related to EV, and 17 clinical questions (CQs) were formulated. PubMed and ICHUSHI Web were searched using the Patient, Intervention, Comparison, and Outcomes terms listed in each CQ as key words. For the classification of new drugs, articles published through February 2021 were selected using the search terms 'extravasation', 'injection-site reaction', 'adverse events', and the names of individual drugs as key words.

RESULTS

Recommendations based on the results of randomized controlled trials (RCTs) were made with regard to the selection of central venous (CV) devices (CQ2, CQ3a, CQ3b, and CQ3c), regular replacement of peripheral venous catheters (CQ5), and use of fosaprepitant (CQ7). These CQs are novel and were not mentioned in previous guidelines. Warm compression monotherapy (CQ10b) and local injection of steroids (CQ12) are discouraged for the management of EV. Ten new drugs were classified for EV tissue injury.

CONCLUSIONS

This study provides updated guidelines for the prevention and treatment of EV, which can be used to help health care providers and patients and their families practice better EV management.

Collapse

Maezawa M, Inoue M, Satake R, Wakabayashi W, Oura K, Miyasaka K, Hirofuji S, Goto F, Iwata M, Suzuki T, Tanaka H, Horibe M, Nakao S, Tsuji T, Ieiri I, Iguchi K, Nakamura M. Profiles and Outcomes of Skin Injuries Caused by Injectable Drug Extravasation: An Analysis of the Japanese Adverse Drug Event Report Database. JOURNAL OF INFUSION NURSING 2023;46:281-293. [PMID: 37611286 DOI: 10.1097/nan.0000000000000517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/25/2023]

Affiliation(s)

Mika Maezawa Laboratories of Drug Informatics (Mss Maezawa, Inoue, Satake, Miyasaka, Hirofuji, and Iwata, Messrs Wakabayashi, Oura, Goto, Suzuki, Tanaka, and Nakao, and Dr Nakamura) and Community Pharmacy (Dr Iguchi), Gifu Pharmaceutical University, Gifu, Japan; Kifune Pharmacy, Gifu, Japan (Ms Iwata); Gifu Prefectural Government, Gifu, Japan (Mr Suzuki); Chubu Yakuhin Co. Ltd., Tajimi, Japan (Mr Tanaka); Department of Nursing, School of Health Science, Asahi University, Mizuho, Japan (Dr Horibe); Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan (Mr Nakao and Drs Tsuji and Ieiri) Mika Maezawa, MS, RN, received her bachelor's and master's degrees in nursing at Yokohama City University in Japan. After receiving her master's degree, she worked as an RN at a university hospital for 3 years. She is a doctoral student at Gifu Pharmaceutical University Misaki Inoue, Riko Satake, Wataru Wakabayashi, Keita Oura, Koumi Miyasaka, Sakiko Hirofuji, and Fumiya Goto are pharmacy students at Gifu Pharmaceutical University Mari Iwata, RPh, Ph, is a pharmacist at Kifune Pharmacy Takaaki Suzuki, RPh, Ph, is an employee of the Gifu Prefectural Government Hideyuki Tanaka, BPharm, Ph, is a pharmacist at Chubu Yakuhin Satoshi Nakao, BPharm, Ph, is a pharmacist at Kyushu University Hospital. They are doctoral students at Gifu Pharmaceutical University Megumi Horibe, PhD, RN, MW, is an associate professor of nursing courses at Asahi University Toshikazu Tsuji, PhD, Ph, is a vice-director of a pharmacy department at Kyushu University Hospital Ichiro Ieiri, PhD, Ph, is a director of a pharmacy department at Kyushu University Hospital Kazuhiro Iguchi, PhD, Ph, is a professor in the community pharmacy at Gifu Pharmaceutical University Mitsuhiro Nakamura, PhD, Ph, is a professor at the Laboratory of Drug Informatics, Gifu Pharmaceutical University
Misaki Inoue Laboratories of Drug Informatics (Mss Maezawa, Inoue, Satake, Miyasaka, Hirofuji, and Iwata, Messrs Wakabayashi, Oura, Goto, Suzuki, Tanaka, and Nakao, and Dr Nakamura) and Community Pharmacy (Dr Iguchi), Gifu Pharmaceutical University, Gifu, Japan; Kifune Pharmacy, Gifu, Japan (Ms Iwata); Gifu Prefectural Government, Gifu, Japan (Mr Suzuki); Chubu Yakuhin Co. Ltd., Tajimi, Japan (Mr Tanaka); Department of Nursing, School of Health Science, Asahi University, Mizuho, Japan (Dr Horibe); Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan (Mr Nakao and Drs Tsuji and Ieiri) Mika Maezawa, MS, RN, received her bachelor's and master's degrees in nursing at Yokohama City University in Japan. After receiving her master's degree, she worked as an RN at a university hospital for 3 years. She is a doctoral student at Gifu Pharmaceutical University Misaki Inoue, Riko Satake, Wataru Wakabayashi, Keita Oura, Koumi Miyasaka, Sakiko Hirofuji, and Fumiya Goto are pharmacy students at Gifu Pharmaceutical University Mari Iwata, RPh, Ph, is a pharmacist at Kifune Pharmacy Takaaki Suzuki, RPh, Ph, is an employee of the Gifu Prefectural Government Hideyuki Tanaka, BPharm, Ph, is a pharmacist at Chubu Yakuhin Satoshi Nakao, BPharm, Ph, is a pharmacist at Kyushu University Hospital. They are doctoral students at Gifu Pharmaceutical University Megumi Horibe, PhD, RN, MW, is an associate professor of nursing courses at Asahi University Toshikazu Tsuji, PhD, Ph, is a vice-director of a pharmacy department at Kyushu University Hospital Ichiro Ieiri, PhD, Ph, is a director of a pharmacy department at Kyushu University Hospital Kazuhiro Iguchi, PhD, Ph, is a professor in the community pharmacy at Gifu Pharmaceutical University Mitsuhiro Nakamura, PhD, Ph, is a professor at the Laboratory of Drug Informatics, Gifu Pharmaceutical University
Riko Satake Laboratories of Drug Informatics (Mss Maezawa, Inoue, Satake, Miyasaka, Hirofuji, and Iwata, Messrs Wakabayashi, Oura, Goto, Suzuki, Tanaka, and Nakao, and Dr Nakamura) and Community Pharmacy (Dr Iguchi), Gifu Pharmaceutical University, Gifu, Japan; Kifune Pharmacy, Gifu, Japan (Ms Iwata); Gifu Prefectural Government, Gifu, Japan (Mr Suzuki); Chubu Yakuhin Co. Ltd., Tajimi, Japan (Mr Tanaka); Department of Nursing, School of Health Science, Asahi University, Mizuho, Japan (Dr Horibe); Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan (Mr Nakao and Drs Tsuji and Ieiri) Mika Maezawa, MS, RN, received her bachelor's and master's degrees in nursing at Yokohama City University in Japan. After receiving her master's degree, she worked as an RN at a university hospital for 3 years. She is a doctoral student at Gifu Pharmaceutical University Misaki Inoue, Riko Satake, Wataru Wakabayashi, Keita Oura, Koumi Miyasaka, Sakiko Hirofuji, and Fumiya Goto are pharmacy students at Gifu Pharmaceutical University Mari Iwata, RPh, Ph, is a pharmacist at Kifune Pharmacy Takaaki Suzuki, RPh, Ph, is an employee of the Gifu Prefectural Government Hideyuki Tanaka, BPharm, Ph, is a pharmacist at Chubu Yakuhin Satoshi Nakao, BPharm, Ph, is a pharmacist at Kyushu University Hospital. They are doctoral students at Gifu Pharmaceutical University Megumi Horibe, PhD, RN, MW, is an associate professor of nursing courses at Asahi University Toshikazu Tsuji, PhD, Ph, is a vice-director of a pharmacy department at Kyushu University Hospital Ichiro Ieiri, PhD, Ph, is a director of a pharmacy department at Kyushu University Hospital Kazuhiro Iguchi, PhD, Ph, is a professor in the community pharmacy at Gifu Pharmaceutical University Mitsuhiro Nakamura, PhD, Ph, is a professor at the Laboratory of Drug Informatics, Gifu Pharmaceutical University
Wataru Wakabayashi Laboratories of Drug Informatics (Mss Maezawa, Inoue, Satake, Miyasaka, Hirofuji, and Iwata, Messrs Wakabayashi, Oura, Goto, Suzuki, Tanaka, and Nakao, and Dr Nakamura) and Community Pharmacy (Dr Iguchi), Gifu Pharmaceutical University, Gifu, Japan; Kifune Pharmacy, Gifu, Japan (Ms Iwata); Gifu Prefectural Government, Gifu, Japan (Mr Suzuki); Chubu Yakuhin Co. Ltd., Tajimi, Japan (Mr Tanaka); Department of Nursing, School of Health Science, Asahi University, Mizuho, Japan (Dr Horibe); Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan (Mr Nakao and Drs Tsuji and Ieiri) Mika Maezawa, MS, RN, received her bachelor's and master's degrees in nursing at Yokohama City University in Japan. After receiving her master's degree, she worked as an RN at a university hospital for 3 years. She is a doctoral student at Gifu Pharmaceutical University Misaki Inoue, Riko Satake, Wataru Wakabayashi, Keita Oura, Koumi Miyasaka, Sakiko Hirofuji, and Fumiya Goto are pharmacy students at Gifu Pharmaceutical University Mari Iwata, RPh, Ph, is a pharmacist at Kifune Pharmacy Takaaki Suzuki, RPh, Ph, is an employee of the Gifu Prefectural Government Hideyuki Tanaka, BPharm, Ph, is a pharmacist at Chubu Yakuhin Satoshi Nakao, BPharm, Ph, is a pharmacist at Kyushu University Hospital. They are doctoral students at Gifu Pharmaceutical University Megumi Horibe, PhD, RN, MW, is an associate professor of nursing courses at Asahi University Toshikazu Tsuji, PhD, Ph, is a vice-director of a pharmacy department at Kyushu University Hospital Ichiro Ieiri, PhD, Ph, is a director of a pharmacy department at Kyushu University Hospital Kazuhiro Iguchi, PhD, Ph, is a professor in the community pharmacy at Gifu Pharmaceutical University Mitsuhiro Nakamura, PhD, Ph, is a professor at the Laboratory of Drug Informatics, Gifu Pharmaceutical University
Keita Oura Laboratories of Drug Informatics (Mss Maezawa, Inoue, Satake, Miyasaka, Hirofuji, and Iwata, Messrs Wakabayashi, Oura, Goto, Suzuki, Tanaka, and Nakao, and Dr Nakamura) and Community Pharmacy (Dr Iguchi), Gifu Pharmaceutical University, Gifu, Japan; Kifune Pharmacy, Gifu, Japan (Ms Iwata); Gifu Prefectural Government, Gifu, Japan (Mr Suzuki); Chubu Yakuhin Co. Ltd., Tajimi, Japan (Mr Tanaka); Department of Nursing, School of Health Science, Asahi University, Mizuho, Japan (Dr Horibe); Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan (Mr Nakao and Drs Tsuji and Ieiri) Mika Maezawa, MS, RN, received her bachelor's and master's degrees in nursing at Yokohama City University in Japan. After receiving her master's degree, she worked as an RN at a university hospital for 3 years. She is a doctoral student at Gifu Pharmaceutical University Misaki Inoue, Riko Satake, Wataru Wakabayashi, Keita Oura, Koumi Miyasaka, Sakiko Hirofuji, and Fumiya Goto are pharmacy students at Gifu Pharmaceutical University Mari Iwata, RPh, Ph, is a pharmacist at Kifune Pharmacy Takaaki Suzuki, RPh, Ph, is an employee of the Gifu Prefectural Government Hideyuki Tanaka, BPharm, Ph, is a pharmacist at Chubu Yakuhin Satoshi Nakao, BPharm, Ph, is a pharmacist at Kyushu University Hospital. They are doctoral students at Gifu Pharmaceutical University Megumi Horibe, PhD, RN, MW, is an associate professor of nursing courses at Asahi University Toshikazu Tsuji, PhD, Ph, is a vice-director of a pharmacy department at Kyushu University Hospital Ichiro Ieiri, PhD, Ph, is a director of a pharmacy department at Kyushu University Hospital Kazuhiro Iguchi, PhD, Ph, is a professor in the community pharmacy at Gifu Pharmaceutical University Mitsuhiro Nakamura, PhD, Ph, is a professor at the Laboratory of Drug Informatics, Gifu Pharmaceutical University
Koumi Miyasaka Laboratories of Drug Informatics (Mss Maezawa, Inoue, Satake, Miyasaka, Hirofuji, and Iwata, Messrs Wakabayashi, Oura, Goto, Suzuki, Tanaka, and Nakao, and Dr Nakamura) and Community Pharmacy (Dr Iguchi), Gifu Pharmaceutical University, Gifu, Japan; Kifune Pharmacy, Gifu, Japan (Ms Iwata); Gifu Prefectural Government, Gifu, Japan (Mr Suzuki); Chubu Yakuhin Co. Ltd., Tajimi, Japan (Mr Tanaka); Department of Nursing, School of Health Science, Asahi University, Mizuho, Japan (Dr Horibe); Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan (Mr Nakao and Drs Tsuji and Ieiri) Mika Maezawa, MS, RN, received her bachelor's and master's degrees in nursing at Yokohama City University in Japan. After receiving her master's degree, she worked as an RN at a university hospital for 3 years. She is a doctoral student at Gifu Pharmaceutical University Misaki Inoue, Riko Satake, Wataru Wakabayashi, Keita Oura, Koumi Miyasaka, Sakiko Hirofuji, and Fumiya Goto are pharmacy students at Gifu Pharmaceutical University Mari Iwata, RPh, Ph, is a pharmacist at Kifune Pharmacy Takaaki Suzuki, RPh, Ph, is an employee of the Gifu Prefectural Government Hideyuki Tanaka, BPharm, Ph, is a pharmacist at Chubu Yakuhin Satoshi Nakao, BPharm, Ph, is a pharmacist at Kyushu University Hospital. They are doctoral students at Gifu Pharmaceutical University Megumi Horibe, PhD, RN, MW, is an associate professor of nursing courses at Asahi University Toshikazu Tsuji, PhD, Ph, is a vice-director of a pharmacy department at Kyushu University Hospital Ichiro Ieiri, PhD, Ph, is a director of a pharmacy department at Kyushu University Hospital Kazuhiro Iguchi, PhD, Ph, is a professor in the community pharmacy at Gifu Pharmaceutical University Mitsuhiro Nakamura, PhD, Ph, is a professor at the Laboratory of Drug Informatics, Gifu Pharmaceutical University
Sakiko Hirofuji Laboratories of Drug Informatics (Mss Maezawa, Inoue, Satake, Miyasaka, Hirofuji, and Iwata, Messrs Wakabayashi, Oura, Goto, Suzuki, Tanaka, and Nakao, and Dr Nakamura) and Community Pharmacy (Dr Iguchi), Gifu Pharmaceutical University, Gifu, Japan; Kifune Pharmacy, Gifu, Japan (Ms Iwata); Gifu Prefectural Government, Gifu, Japan (Mr Suzuki); Chubu Yakuhin Co. Ltd., Tajimi, Japan (Mr Tanaka); Department of Nursing, School of Health Science, Asahi University, Mizuho, Japan (Dr Horibe); Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan (Mr Nakao and Drs Tsuji and Ieiri) Mika Maezawa, MS, RN, received her bachelor's and master's degrees in nursing at Yokohama City University in Japan. After receiving her master's degree, she worked as an RN at a university hospital for 3 years. She is a doctoral student at Gifu Pharmaceutical University Misaki Inoue, Riko Satake, Wataru Wakabayashi, Keita Oura, Koumi Miyasaka, Sakiko Hirofuji, and Fumiya Goto are pharmacy students at Gifu Pharmaceutical University Mari Iwata, RPh, Ph, is a pharmacist at Kifune Pharmacy Takaaki Suzuki, RPh, Ph, is an employee of the Gifu Prefectural Government Hideyuki Tanaka, BPharm, Ph, is a pharmacist at Chubu Yakuhin Satoshi Nakao, BPharm, Ph, is a pharmacist at Kyushu University Hospital. They are doctoral students at Gifu Pharmaceutical University Megumi Horibe, PhD, RN, MW, is an associate professor of nursing courses at Asahi University Toshikazu Tsuji, PhD, Ph, is a vice-director of a pharmacy department at Kyushu University Hospital Ichiro Ieiri, PhD, Ph, is a director of a pharmacy department at Kyushu University Hospital Kazuhiro Iguchi, PhD, Ph, is a professor in the community pharmacy at Gifu Pharmaceutical University Mitsuhiro Nakamura, PhD, Ph, is a professor at the Laboratory of Drug Informatics, Gifu Pharmaceutical University
Fumiya Goto Laboratories of Drug Informatics (Mss Maezawa, Inoue, Satake, Miyasaka, Hirofuji, and Iwata, Messrs Wakabayashi, Oura, Goto, Suzuki, Tanaka, and Nakao, and Dr Nakamura) and Community Pharmacy (Dr Iguchi), Gifu Pharmaceutical University, Gifu, Japan; Kifune Pharmacy, Gifu, Japan (Ms Iwata); Gifu Prefectural Government, Gifu, Japan (Mr Suzuki); Chubu Yakuhin Co. Ltd., Tajimi, Japan (Mr Tanaka); Department of Nursing, School of Health Science, Asahi University, Mizuho, Japan (Dr Horibe); Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan (Mr Nakao and Drs Tsuji and Ieiri) Mika Maezawa, MS, RN, received her bachelor's and master's degrees in nursing at Yokohama City University in Japan. After receiving her master's degree, she worked as an RN at a university hospital for 3 years. She is a doctoral student at Gifu Pharmaceutical University Misaki Inoue, Riko Satake, Wataru Wakabayashi, Keita Oura, Koumi Miyasaka, Sakiko Hirofuji, and Fumiya Goto are pharmacy students at Gifu Pharmaceutical University Mari Iwata, RPh, Ph, is a pharmacist at Kifune Pharmacy Takaaki Suzuki, RPh, Ph, is an employee of the Gifu Prefectural Government Hideyuki Tanaka, BPharm, Ph, is a pharmacist at Chubu Yakuhin Satoshi Nakao, BPharm, Ph, is a pharmacist at Kyushu University Hospital. They are doctoral students at Gifu Pharmaceutical University Megumi Horibe, PhD, RN, MW, is an associate professor of nursing courses at Asahi University Toshikazu Tsuji, PhD, Ph, is a vice-director of a pharmacy department at Kyushu University Hospital Ichiro Ieiri, PhD, Ph, is a director of a pharmacy department at Kyushu University Hospital Kazuhiro Iguchi, PhD, Ph, is a professor in the community pharmacy at Gifu Pharmaceutical University Mitsuhiro Nakamura, PhD, Ph, is a professor at the Laboratory of Drug Informatics, Gifu Pharmaceutical University
Mari Iwata Laboratories of Drug Informatics (Mss Maezawa, Inoue, Satake, Miyasaka, Hirofuji, and Iwata, Messrs Wakabayashi, Oura, Goto, Suzuki, Tanaka, and Nakao, and Dr Nakamura) and Community Pharmacy (Dr Iguchi), Gifu Pharmaceutical University, Gifu, Japan; Kifune Pharmacy, Gifu, Japan (Ms Iwata); Gifu Prefectural Government, Gifu, Japan (Mr Suzuki); Chubu Yakuhin Co. Ltd., Tajimi, Japan (Mr Tanaka); Department of Nursing, School of Health Science, Asahi University, Mizuho, Japan (Dr Horibe); Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan (Mr Nakao and Drs Tsuji and Ieiri) Mika Maezawa, MS, RN, received her bachelor's and master's degrees in nursing at Yokohama City University in Japan. After receiving her master's degree, she worked as an RN at a university hospital for 3 years. She is a doctoral student at Gifu Pharmaceutical University Misaki Inoue, Riko Satake, Wataru Wakabayashi, Keita Oura, Koumi Miyasaka, Sakiko Hirofuji, and Fumiya Goto are pharmacy students at Gifu Pharmaceutical University Mari Iwata, RPh, Ph, is a pharmacist at Kifune Pharmacy Takaaki Suzuki, RPh, Ph, is an employee of the Gifu Prefectural Government Hideyuki Tanaka, BPharm, Ph, is a pharmacist at Chubu Yakuhin Satoshi Nakao, BPharm, Ph, is a pharmacist at Kyushu University Hospital. They are doctoral students at Gifu Pharmaceutical University Megumi Horibe, PhD, RN, MW, is an associate professor of nursing courses at Asahi University Toshikazu Tsuji, PhD, Ph, is a vice-director of a pharmacy department at Kyushu University Hospital Ichiro Ieiri, PhD, Ph, is a director of a pharmacy department at Kyushu University Hospital Kazuhiro Iguchi, PhD, Ph, is a professor in the community pharmacy at Gifu Pharmaceutical University Mitsuhiro Nakamura, PhD, Ph, is a professor at the Laboratory of Drug Informatics, Gifu Pharmaceutical University
Takaaki Suzuki Laboratories of Drug Informatics (Mss Maezawa, Inoue, Satake, Miyasaka, Hirofuji, and Iwata, Messrs Wakabayashi, Oura, Goto, Suzuki, Tanaka, and Nakao, and Dr Nakamura) and Community Pharmacy (Dr Iguchi), Gifu Pharmaceutical University, Gifu, Japan; Kifune Pharmacy, Gifu, Japan (Ms Iwata); Gifu Prefectural Government, Gifu, Japan (Mr Suzuki); Chubu Yakuhin Co. Ltd., Tajimi, Japan (Mr Tanaka); Department of Nursing, School of Health Science, Asahi University, Mizuho, Japan (Dr Horibe); Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan (Mr Nakao and Drs Tsuji and Ieiri) Mika Maezawa, MS, RN, received her bachelor's and master's degrees in nursing at Yokohama City University in Japan. After receiving her master's degree, she worked as an RN at a university hospital for 3 years. She is a doctoral student at Gifu Pharmaceutical University Misaki Inoue, Riko Satake, Wataru Wakabayashi, Keita Oura, Koumi Miyasaka, Sakiko Hirofuji, and Fumiya Goto are pharmacy students at Gifu Pharmaceutical University Mari Iwata, RPh, Ph, is a pharmacist at Kifune Pharmacy Takaaki Suzuki, RPh, Ph, is an employee of the Gifu Prefectural Government Hideyuki Tanaka, BPharm, Ph, is a pharmacist at Chubu Yakuhin Satoshi Nakao, BPharm, Ph, is a pharmacist at Kyushu University Hospital. They are doctoral students at Gifu Pharmaceutical University Megumi Horibe, PhD, RN, MW, is an associate professor of nursing courses at Asahi University Toshikazu Tsuji, PhD, Ph, is a vice-director of a pharmacy department at Kyushu University Hospital Ichiro Ieiri, PhD, Ph, is a director of a pharmacy department at Kyushu University Hospital Kazuhiro Iguchi, PhD, Ph, is a professor in the community pharmacy at Gifu Pharmaceutical University Mitsuhiro Nakamura, PhD, Ph, is a professor at the Laboratory of Drug Informatics, Gifu Pharmaceutical University
Hideyuki Tanaka Laboratories of Drug Informatics (Mss Maezawa, Inoue, Satake, Miyasaka, Hirofuji, and Iwata, Messrs Wakabayashi, Oura, Goto, Suzuki, Tanaka, and Nakao, and Dr Nakamura) and Community Pharmacy (Dr Iguchi), Gifu Pharmaceutical University, Gifu, Japan; Kifune Pharmacy, Gifu, Japan (Ms Iwata); Gifu Prefectural Government, Gifu, Japan (Mr Suzuki); Chubu Yakuhin Co. Ltd., Tajimi, Japan (Mr Tanaka); Department of Nursing, School of Health Science, Asahi University, Mizuho, Japan (Dr Horibe); Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan (Mr Nakao and Drs Tsuji and Ieiri) Mika Maezawa, MS, RN, received her bachelor's and master's degrees in nursing at Yokohama City University in Japan. After receiving her master's degree, she worked as an RN at a university hospital for 3 years. She is a doctoral student at Gifu Pharmaceutical University Misaki Inoue, Riko Satake, Wataru Wakabayashi, Keita Oura, Koumi Miyasaka, Sakiko Hirofuji, and Fumiya Goto are pharmacy students at Gifu Pharmaceutical University Mari Iwata, RPh, Ph, is a pharmacist at Kifune Pharmacy Takaaki Suzuki, RPh, Ph, is an employee of the Gifu Prefectural Government Hideyuki Tanaka, BPharm, Ph, is a pharmacist at Chubu Yakuhin Satoshi Nakao, BPharm, Ph, is a pharmacist at Kyushu University Hospital. They are doctoral students at Gifu Pharmaceutical University Megumi Horibe, PhD, RN, MW, is an associate professor of nursing courses at Asahi University Toshikazu Tsuji, PhD, Ph, is a vice-director of a pharmacy department at Kyushu University Hospital Ichiro Ieiri, PhD, Ph, is a director of a pharmacy department at Kyushu University Hospital Kazuhiro Iguchi, PhD, Ph, is a professor in the community pharmacy at Gifu Pharmaceutical University Mitsuhiro Nakamura, PhD, Ph, is a professor at the Laboratory of Drug Informatics, Gifu Pharmaceutical University
Megumi Horibe Laboratories of Drug Informatics (Mss Maezawa, Inoue, Satake, Miyasaka, Hirofuji, and Iwata, Messrs Wakabayashi, Oura, Goto, Suzuki, Tanaka, and Nakao, and Dr Nakamura) and Community Pharmacy (Dr Iguchi), Gifu Pharmaceutical University, Gifu, Japan; Kifune Pharmacy, Gifu, Japan (Ms Iwata); Gifu Prefectural Government, Gifu, Japan (Mr Suzuki); Chubu Yakuhin Co. Ltd., Tajimi, Japan (Mr Tanaka); Department of Nursing, School of Health Science, Asahi University, Mizuho, Japan (Dr Horibe); Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan (Mr Nakao and Drs Tsuji and Ieiri) Mika Maezawa, MS, RN, received her bachelor's and master's degrees in nursing at Yokohama City University in Japan. After receiving her master's degree, she worked as an RN at a university hospital for 3 years. She is a doctoral student at Gifu Pharmaceutical University Misaki Inoue, Riko Satake, Wataru Wakabayashi, Keita Oura, Koumi Miyasaka, Sakiko Hirofuji, and Fumiya Goto are pharmacy students at Gifu Pharmaceutical University Mari Iwata, RPh, Ph, is a pharmacist at Kifune Pharmacy Takaaki Suzuki, RPh, Ph, is an employee of the Gifu Prefectural Government Hideyuki Tanaka, BPharm, Ph, is a pharmacist at Chubu Yakuhin Satoshi Nakao, BPharm, Ph, is a pharmacist at Kyushu University Hospital. They are doctoral students at Gifu Pharmaceutical University Megumi Horibe, PhD, RN, MW, is an associate professor of nursing courses at Asahi University Toshikazu Tsuji, PhD, Ph, is a vice-director of a pharmacy department at Kyushu University Hospital Ichiro Ieiri, PhD, Ph, is a director of a pharmacy department at Kyushu University Hospital Kazuhiro Iguchi, PhD, Ph, is a professor in the community pharmacy at Gifu Pharmaceutical University Mitsuhiro Nakamura, PhD, Ph, is a professor at the Laboratory of Drug Informatics, Gifu Pharmaceutical University
Satoshi Nakao Laboratories of Drug Informatics (Mss Maezawa, Inoue, Satake, Miyasaka, Hirofuji, and Iwata, Messrs Wakabayashi, Oura, Goto, Suzuki, Tanaka, and Nakao, and Dr Nakamura) and Community Pharmacy (Dr Iguchi), Gifu Pharmaceutical University, Gifu, Japan; Kifune Pharmacy, Gifu, Japan (Ms Iwata); Gifu Prefectural Government, Gifu, Japan (Mr Suzuki); Chubu Yakuhin Co. Ltd., Tajimi, Japan (Mr Tanaka); Department of Nursing, School of Health Science, Asahi University, Mizuho, Japan (Dr Horibe); Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan (Mr Nakao and Drs Tsuji and Ieiri) Mika Maezawa, MS, RN, received her bachelor's and master's degrees in nursing at Yokohama City University in Japan. After receiving her master's degree, she worked as an RN at a university hospital for 3 years. She is a doctoral student at Gifu Pharmaceutical University Misaki Inoue, Riko Satake, Wataru Wakabayashi, Keita Oura, Koumi Miyasaka, Sakiko Hirofuji, and Fumiya Goto are pharmacy students at Gifu Pharmaceutical University Mari Iwata, RPh, Ph, is a pharmacist at Kifune Pharmacy Takaaki Suzuki, RPh, Ph, is an employee of the Gifu Prefectural Government Hideyuki Tanaka, BPharm, Ph, is a pharmacist at Chubu Yakuhin Satoshi Nakao, BPharm, Ph, is a pharmacist at Kyushu University Hospital. They are doctoral students at Gifu Pharmaceutical University Megumi Horibe, PhD, RN, MW, is an associate professor of nursing courses at Asahi University Toshikazu Tsuji, PhD, Ph, is a vice-director of a pharmacy department at Kyushu University Hospital Ichiro Ieiri, PhD, Ph, is a director of a pharmacy department at Kyushu University Hospital Kazuhiro Iguchi, PhD, Ph, is a professor in the community pharmacy at Gifu Pharmaceutical University Mitsuhiro Nakamura, PhD, Ph, is a professor at the Laboratory of Drug Informatics, Gifu Pharmaceutical University
Toshikazu Tsuji Laboratories of Drug Informatics (Mss Maezawa, Inoue, Satake, Miyasaka, Hirofuji, and Iwata, Messrs Wakabayashi, Oura, Goto, Suzuki, Tanaka, and Nakao, and Dr Nakamura) and Community Pharmacy (Dr Iguchi), Gifu Pharmaceutical University, Gifu, Japan; Kifune Pharmacy, Gifu, Japan (Ms Iwata); Gifu Prefectural Government, Gifu, Japan (Mr Suzuki); Chubu Yakuhin Co. Ltd., Tajimi, Japan (Mr Tanaka); Department of Nursing, School of Health Science, Asahi University, Mizuho, Japan (Dr Horibe); Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan (Mr Nakao and Drs Tsuji and Ieiri) Mika Maezawa, MS, RN, received her bachelor's and master's degrees in nursing at Yokohama City University in Japan. After receiving her master's degree, she worked as an RN at a university hospital for 3 years. She is a doctoral student at Gifu Pharmaceutical University Misaki Inoue, Riko Satake, Wataru Wakabayashi, Keita Oura, Koumi Miyasaka, Sakiko Hirofuji, and Fumiya Goto are pharmacy students at Gifu Pharmaceutical University Mari Iwata, RPh, Ph, is a pharmacist at Kifune Pharmacy Takaaki Suzuki, RPh, Ph, is an employee of the Gifu Prefectural Government Hideyuki Tanaka, BPharm, Ph, is a pharmacist at Chubu Yakuhin Satoshi Nakao, BPharm, Ph, is a pharmacist at Kyushu University Hospital. They are doctoral students at Gifu Pharmaceutical University Megumi Horibe, PhD, RN, MW, is an associate professor of nursing courses at Asahi University Toshikazu Tsuji, PhD, Ph, is a vice-director of a pharmacy department at Kyushu University Hospital Ichiro Ieiri, PhD, Ph, is a director of a pharmacy department at Kyushu University Hospital Kazuhiro Iguchi, PhD, Ph, is a professor in the community pharmacy at Gifu Pharmaceutical University Mitsuhiro Nakamura, PhD, Ph, is a professor at the Laboratory of Drug Informatics, Gifu Pharmaceutical University
Ichiro Ieiri Laboratories of Drug Informatics (Mss Maezawa, Inoue, Satake, Miyasaka, Hirofuji, and Iwata, Messrs Wakabayashi, Oura, Goto, Suzuki, Tanaka, and Nakao, and Dr Nakamura) and Community Pharmacy (Dr Iguchi), Gifu Pharmaceutical University, Gifu, Japan; Kifune Pharmacy, Gifu, Japan (Ms Iwata); Gifu Prefectural Government, Gifu, Japan (Mr Suzuki); Chubu Yakuhin Co. Ltd., Tajimi, Japan (Mr Tanaka); Department of Nursing, School of Health Science, Asahi University, Mizuho, Japan (Dr Horibe); Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan (Mr Nakao and Drs Tsuji and Ieiri) Mika Maezawa, MS, RN, received her bachelor's and master's degrees in nursing at Yokohama City University in Japan. After receiving her master's degree, she worked as an RN at a university hospital for 3 years. She is a doctoral student at Gifu Pharmaceutical University Misaki Inoue, Riko Satake, Wataru Wakabayashi, Keita Oura, Koumi Miyasaka, Sakiko Hirofuji, and Fumiya Goto are pharmacy students at Gifu Pharmaceutical University Mari Iwata, RPh, Ph, is a pharmacist at Kifune Pharmacy Takaaki Suzuki, RPh, Ph, is an employee of the Gifu Prefectural Government Hideyuki Tanaka, BPharm, Ph, is a pharmacist at Chubu Yakuhin Satoshi Nakao, BPharm, Ph, is a pharmacist at Kyushu University Hospital. They are doctoral students at Gifu Pharmaceutical University Megumi Horibe, PhD, RN, MW, is an associate professor of nursing courses at Asahi University Toshikazu Tsuji, PhD, Ph, is a vice-director of a pharmacy department at Kyushu University Hospital Ichiro Ieiri, PhD, Ph, is a director of a pharmacy department at Kyushu University Hospital Kazuhiro Iguchi, PhD, Ph, is a professor in the community pharmacy at Gifu Pharmaceutical University Mitsuhiro Nakamura, PhD, Ph, is a professor at the Laboratory of Drug Informatics, Gifu Pharmaceutical University
Kazuhiro Iguchi Laboratories of Drug Informatics (Mss Maezawa, Inoue, Satake, Miyasaka, Hirofuji, and Iwata, Messrs Wakabayashi, Oura, Goto, Suzuki, Tanaka, and Nakao, and Dr Nakamura) and Community Pharmacy (Dr Iguchi), Gifu Pharmaceutical University, Gifu, Japan; Kifune Pharmacy, Gifu, Japan (Ms Iwata); Gifu Prefectural Government, Gifu, Japan (Mr Suzuki); Chubu Yakuhin Co. Ltd., Tajimi, Japan (Mr Tanaka); Department of Nursing, School of Health Science, Asahi University, Mizuho, Japan (Dr Horibe); Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan (Mr Nakao and Drs Tsuji and Ieiri) Mika Maezawa, MS, RN, received her bachelor's and master's degrees in nursing at Yokohama City University in Japan. After receiving her master's degree, she worked as an RN at a university hospital for 3 years. She is a doctoral student at Gifu Pharmaceutical University Misaki Inoue, Riko Satake, Wataru Wakabayashi, Keita Oura, Koumi Miyasaka, Sakiko Hirofuji, and Fumiya Goto are pharmacy students at Gifu Pharmaceutical University Mari Iwata, RPh, Ph, is a pharmacist at Kifune Pharmacy Takaaki Suzuki, RPh, Ph, is an employee of the Gifu Prefectural Government Hideyuki Tanaka, BPharm, Ph, is a pharmacist at Chubu Yakuhin Satoshi Nakao, BPharm, Ph, is a pharmacist at Kyushu University Hospital. They are doctoral students at Gifu Pharmaceutical University Megumi Horibe, PhD, RN, MW, is an associate professor of nursing courses at Asahi University Toshikazu Tsuji, PhD, Ph, is a vice-director of a pharmacy department at Kyushu University Hospital Ichiro Ieiri, PhD, Ph, is a director of a pharmacy department at Kyushu University Hospital Kazuhiro Iguchi, PhD, Ph, is a professor in the community pharmacy at Gifu Pharmaceutical University Mitsuhiro Nakamura, PhD, Ph, is a professor at the Laboratory of Drug Informatics, Gifu Pharmaceutical University
Mitsuhiro Nakamura Laboratories of Drug Informatics (Mss Maezawa, Inoue, Satake, Miyasaka, Hirofuji, and Iwata, Messrs Wakabayashi, Oura, Goto, Suzuki, Tanaka, and Nakao, and Dr Nakamura) and Community Pharmacy (Dr Iguchi), Gifu Pharmaceutical University, Gifu, Japan; Kifune Pharmacy, Gifu, Japan (Ms Iwata); Gifu Prefectural Government, Gifu, Japan (Mr Suzuki); Chubu Yakuhin Co. Ltd., Tajimi, Japan (Mr Tanaka); Department of Nursing, School of Health Science, Asahi University, Mizuho, Japan (Dr Horibe); Department of Pharmacy, Kyushu University Hospital, Fukuoka, Japan (Mr Nakao and Drs Tsuji and Ieiri) Mika Maezawa, MS, RN, received her bachelor's and master's degrees in nursing at Yokohama City University in Japan. After receiving her master's degree, she worked as an RN at a university hospital for 3 years. She is a doctoral student at Gifu Pharmaceutical University Misaki Inoue, Riko Satake, Wataru Wakabayashi, Keita Oura, Koumi Miyasaka, Sakiko Hirofuji, and Fumiya Goto are pharmacy students at Gifu Pharmaceutical University Mari Iwata, RPh, Ph, is a pharmacist at Kifune Pharmacy Takaaki Suzuki, RPh, Ph, is an employee of the Gifu Prefectural Government Hideyuki Tanaka, BPharm, Ph, is a pharmacist at Chubu Yakuhin Satoshi Nakao, BPharm, Ph, is a pharmacist at Kyushu University Hospital. They are doctoral students at Gifu Pharmaceutical University Megumi Horibe, PhD, RN, MW, is an associate professor of nursing courses at Asahi University Toshikazu Tsuji, PhD, Ph, is a vice-director of a pharmacy department at Kyushu University Hospital Ichiro Ieiri, PhD, Ph, is a director of a pharmacy department at Kyushu University Hospital Kazuhiro Iguchi, PhD, Ph, is a professor in the community pharmacy at Gifu Pharmaceutical University Mitsuhiro Nakamura, PhD, Ph, is a professor at the Laboratory of Drug Informatics, Gifu Pharmaceutical University

Collapse

Dranitsaris G, Moezi M, Dobson K, Phelan R, Blau S. A real-world study to evaluate the safety and efficacy of three injectable neurokinin-1 receptor antagonist formulations for the prevention of chemotherapy-induced nausea and vomiting in cancer patients. Support Care Cancer 2022;30:6649-6658. [PMID: 35499619 PMCID: PMC9213362 DOI: 10.1007/s00520-022-07082-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2021] [Accepted: 04/20/2022] [Indexed: 10/31/2022]

Abstract Abstract Background Three different injectable neurokinin-1 (NK-1) receptor antagonist formulations (CINVANTI® [C] vs. intravenous Emend® [E] vs. generic formulations of fosaprepitant [GFF]) were compared with respect to nausea and vomiting control, use of rescue therapy, and the development of infusion reactions over multiple cycles of chemotherapy. Methods A retrospective analysis from 17 community oncology practices across the USA was conducted on patients who received moderately or highly emetogenic chemotherapy. The co-primary endpoints were the control of chemotherapy-induced nausea and vomiting (CINV) from days 1 to 5 over all cycles and the frequency of infusion-related reactions. Propensity score weighted multivariable logistic regression analysis was used to compare complete CINV control, the use of rescue therapy, and the risk of infusion reactions between groups. Results The study enrolled 294 patients (C = 101, E = 101, GFF = 92) who received 1432 cycles of chemotherapy. Using CINVANTI® as the reference group, comparative effectiveness was suggested in CINV control over all chemotherapy cycles (odds ratio (OR): E vs. C = 1.00 [0.54 to 1.86] and GFF vs. C = 1.12 [0.54 to 2.32]). However, use of rescue therapy was significantly higher in the EMEND® group relative to CINVANTI® (OR = 2.69; 95%CI: 1.06 to 6.84). Infusion reactions were also numerically higher in the EMEND® group, but the difference did not reach statistical significance (OR = 4.35; 95%CI: 0.83 to 22.8). Conclusions In this real-world analysis, patients receiving CINVANTI® had a reduced need for CINV rescue therapy and a numerically lower incidence of infusion reactions. Collapse

Matsuura K, Tsurutani J, Inoue K, Tanabe Y, Taira T, Kubota K, Tamura T, Saeki T. A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC. Cancer 2022;128:1692-1698. [PMID: 35045185 PMCID: PMC9306508 DOI: 10.1002/cncr.34088] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2021] [Revised: 12/10/2021] [Accepted: 12/13/2021] [Indexed: 11/22/2022]

Abstract

BACKGROUND

Fosnetupitant (FosNTP), an intravenous neurokinin 1 receptor antagonist, demonstrated a favorable safety profile with a potentially low risk of injection site reactions (ISRs) and promising antiemetic efficacy in patients receiving cisplatin‐based highly emetogenic chemotherapy in a previous phase 2 study. We conducted a randomized, double‐blind safety study to evaluate the safety profile of FosNTP, including ISRs, in patients receiving doxorubicin‐cyclophosphamide or epirubicin‐cyclophosphamide (AC/EC) chemotherapy.

METHODS

Patients scheduled to receive AC/EC were randomized 1:1 to receive 235 mg of FosNTP or 150 mg of fosaprepitant (FosAPR), both in combination with 0.75 mg of intravenous palonosetron and 9.9 mg of dexamethasone on day 1. The stratification factors were age category (<55 vs ≥55 years) and study site. The primary end point was the incidence of treatment‐related adverse events (TRAEs) with FosNTP.

RESULTS

Overall, 102 patients were randomized to FosNTP (n = 52) or FosAPR (n = 50), and all were treated with the study drug and evaluated for safety. The primary end point, the incidence of TRAEs, was similar with FosNTP (21.2%; 95% confidence interval [CI], 11.1%‐34.7%) and FosAPR (22.0%; 95% CI, 11.5%‐36.0%), with any‐cause ISRs observed in 5.8% and 26.0% of patients, respectively, and treatment‐related ISRs observed in 0% and 10.0%, respectively. The overall (0‐120 hour) complete response (defined as no emetic event and no rescue medication) rate, standardized by age category in the full analysis set, was 45.9% (23 of 51 patients) with FosNTP and 51.3% (25 of 49 patients) with FosAPR.

CONCLUSIONS

FosNTP demonstrated a favorable safety profile with a very low risk of ISRs in the AC/EC setting.

Fosnetupitant shows a favorable safety profile in patients receiving doxorubicin‐cyclophosphamide or epirubicin‐cyclophosphamide chemotherapy. As an intravenous neurokinin 1 receptor antagonist with a low risk of causing injection site reactions, fosnetupitant may be used for protecting patients with cancer from experiencing chemotherapy‐induced nausea and vomiting.

Collapse

Hata A, Okamoto I, Inui N, Okada M, Morise M, Akiyoshi K, Takeda M, Watanabe Y, Sugawara S, Shinagawa N, Kubota K, Saeki T, Tamura T. Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE. J Clin Oncol 2022;40:180-188. [PMID: 34793245 PMCID: PMC8718175 DOI: 10.1200/jco.21.01315] [Citation(s) in RCA: 25] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Revised: 09/29/2021] [Accepted: 10/12/2021] [Indexed: 01/12/2023] Open

Abstract

PURPOSE

We evaluated the efficacy and safety of fosnetupitant (FosNTP) versus fosaprepitant (FosAPR) for preventing highly emetogenic chemotherapy-induced nausea and vomiting. This phase III study was the first head-to-head comparison between two different neurokinin-1 receptor antagonists in combination with palonosetron and dexamethasone.

PATIENTS AND METHODS

Patients scheduled to receive cisplatin-based chemotherapy were randomly assigned 1:1 to FosNTP 235 mg or FosAPR 150 mg in combination with palonosetron 0.75 mg and dexamethasone. The primary end point was overall (0-120 hours) complete response (CR; no emetic event and no rescue medication) rate, stratified by sex and age category, to show the noninferiority of FosNTP to FosAPR (noninferiority margin, -10% for the difference in the overall CR rate).

RESULTS

Overall, 795 patients were randomly assigned, of whom 785 received the study drug (FosNTP [N = 392] v FosAPR [N = 393]) and were evaluated for efficacy and safety. The overall CR rate was 75.2% versus 71.0%, respectively (Mantel-Haenszel common risk difference, 4.1%; 95% CI, -2.1% to 10.3%), demonstrating noninferiority of FosNTP to FosAPR. The CR rates in the acute (0-24 hours), delayed (24-120 hours), and beyond delayed (120-168 hours) phases, and at 0-168 hours were 93.9% versus 92.6%, 76.8% versus 72.8%, 86.5% versus 81.4%, and 73.2% versus 66.9%, respectively. The incidence rates of treatment-related adverse events with FosNTP versus FosAPR were 22.2% versus 25.4%, whereas adverse events or treatment-related adverse events relevant to injection site reactions were 11.0% versus 20.6% (P < .001) and 0.3% versus 3.6% (P < .001), respectively.

CONCLUSION

FosNTP demonstrated noninferiority to FosAPR, with a favorable safety profile and lower risk for injection site reactions. Thus, FosNTP is valuable in the prophylaxis of acute, delayed, and beyond delayed chemotherapy-induced nausea and vomiting.

Collapse

Segna AN, Baron RH, Cohen B. Infusion Site Reactions: Classification in the Setting of Fosaprepitant Administration With Chemotherapy. Clin J Oncol Nurs 2020;24:E79-E84. [PMID: 33216065 DOI: 10.1188/20.cjon.e79-e84] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]

The next generation of antiemetics for the management of postoperative nausea and vomiting. Best Pract Res Clin Anaesthesiol 2020;34:759-769. [PMID: 33288125 DOI: 10.1016/j.bpa.2020.11.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2020] [Accepted: 11/09/2020] [Indexed: 11/23/2022]

Aapro M, Navari RM, Roeland E, Zhang L, Schwartzberg L. Efficacy of intravenous NEPA, a fixed NK₁/5-HT₃ receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies. Crit Rev Oncol Hematol 2020;157:103143. [PMID: 33260048 DOI: 10.1016/j.critrevonc.2020.103143] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2020] [Revised: 10/20/2020] [Accepted: 10/21/2020] [Indexed: 11/25/2022] Open

Schwartzberg L, Navari R, Clark‐Snow R, Arkania E, Radyukova I, Patel K, Voisin D, Rizzi G, Wickham R, Gralla RJ, Aapro M, Roeland E. Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy. Oncologist 2020;25:e589-e597. [PMID: 32162813 PMCID: PMC7066686 DOI: 10.1634/theoncologist.2019-0527] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2019] [Accepted: 11/01/2019] [Indexed: 11/23/2022] Open

Abstract

BACKGROUND

NEPA, a combination antiemetic of a neurokinin-1 (NK1 ) receptor antagonist (RA) (netupitant [oral]/fosnetupitant [intravenous; IV]) and 5-HT3 RA, palonosetron] offers 5-day CINV prevention with a single dose. Fosnetupitant solution contains no allergenic excipients, surfactant, emulsifier, or solubility enhancer. A phase III study of patients receiving cisplatin found no infusion-site or anaphylactic reactions related to IV NEPA. However, hypersensitivity reactions and anaphylaxis have been reported with other IV NK1 RAs, particularly fosaprepitant in patients receiving anthracycline-cyclophosphamide (AC)-based chemotherapy. This study evaluated the safety and efficacy of IV NEPA in the AC setting.

MATERIALS AND METHODS

This phase IIIb, multinational, randomized, double-blind study enrolled females with breast cancer naive to highly or moderately emetogenic chemotherapy. Patients were randomized to receive a single 30-minute infusion of IV NEPA or single oral NEPA capsule on day 1 prior to AC, in repeated (up to 4) cycles. Oral dexamethasone was given to all patients on day 1 only.

RESULTS

A total of 402 patients were included. The adverse event (AE) profiles were similar for IV and oral NEPA and consistent with those expected. Most AEs were mild or moderate with a similarly low incidence of treatment-related AEs in both groups. There were no treatment-related injection-site AEs and no reports of hypersensitivity or anaphylaxis. The efficacy of IV and oral NEPA were similar, with high complete response (no emesis/no rescue) rates observed in cycle 1 (overall [0-120 hours] 73.0% IV NEPA, 77.3% oral NEPA) and maintained over subsequent cycles.

CONCLUSION

IV NEPA was highly effective and safe with no associated hypersensitivity and injection-site reactions in patients receiving AC.

IMPLICATIONS FOR PRACTICE

As a combination of a neurokinin-1 (NK1 ) receptor antagonist (RA) and 5-HT3 RA, NEPA offers 5-day chemotherapy-induced nausea and vomiting prevention with a single dose and an opportunity to improve adherence to antiemetic guidelines. In this randomized multinational phase IIIb study, intravenous (IV) NEPA (fosnetupitant/palonosetron) was safe and highly effective in patients receiving multiple cycles of anthracycline-cyclophosphamide (AC)-based chemotherapy. Unlike other IV NK1 RAs, the IV NEPA combination solution does not require any surfactant, emulsifier, or solubility enhancer and contains no allergenic excipients. Hypersensitivity reactions and anaphylaxis have been reported with other IV NK1 RAs, most commonly with fosaprepitant in the AC setting. Importantly, there were no injection-site or hypersensitivity reactions associated with IV NEPA.

Collapse

Navari RM. Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review. Expert Opin Drug Saf 2019;19:205-210. [PMID: 31709853 DOI: 10.1080/14740338.2020.1691521] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]

Karthaus M, Schiel X, Ruhlmann CH, Celio L. Neurokinin-1 receptor antagonists: review of their role for the prevention of chemotherapy-induced nausea and vomiting in adults. Expert Rev Clin Pharmacol 2019;12:661-680. [PMID: 31194593 DOI: 10.1080/17512433.2019.1621162] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]

Roberts R, Hanna L, Borley A, Dolan G, Williams EM. Epirubicin chemotherapy in women with breast cancer: Alternating arms for intravenous administration to reduce chemical phlebitis. Eur J Cancer Care (Engl) 2019;28:e13114. [PMID: 31148328 DOI: 10.1111/ecc.13114] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2019] [Revised: 04/21/2019] [Accepted: 05/14/2019] [Indexed: 12/09/2022]

Walton GD. Safety Profile of HTX-019 Administered as an Intravenous Push in Cancer Patients: A Retrospective Review. Adv Ther 2019;36:662-669. [PMID: 30706408 PMCID: PMC6824338 DOI: 10.1007/s12325-019-0877-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2018] [Indexed: 11/28/2022]

Abstract

INTRODUCTION

HTX-019 [CINVANTI® (aprepitant injectable emulsion)] is a neurokinin 1 receptor antagonist (NK-1 RA) approved as a 30-min infusion for preventing acute and delayed chemotherapy-induced nausea and vomiting. HTX-019 has been generally well tolerated when administered as a 30-min infusion or 2-min injection [intravenous (IV) push] in healthy subjects. This real-world analysis assesses safety of HTX-019 via IV push in patients with cancer and addresses a recent IV bag shortage.

METHODS

This retrospective review involved six sites in Alabama, USA. Analyzed patients were 18-94 years old with an Eastern Cooperative Oncology Group performance status ranging from 0 to 4. Seventy-six chemotherapy regimens were utilized (emetogenicity high, n = 35; moderate, n = 35; low, n = 6) and patients received HTX-019 130 mg only or switched from fosaprepitant 150 mg to HTX-019 130 mg within a three-drug antiemetic regimen with a 5-hydroxytryptamine type 3 RA and dexamethasone. HTX-019 was administered via IV push. Electronic medical records of patients receiving HTX-019 were queried for nursing and medical documentation associated with infusion-site adverse events (ISAEs). The detailed notes were also reviewed for any discontinuation of HTX-019 or substitution of HTX-019 with another NK-1 RA.

RESULTS

The HTX-019 safety profile was analyzed on the basis of 2066 IV push administrations in 591 cancer patients (most common diagnoses: lung, n = 107; breast, n = 100; colon, n = 92). No clinically significant ISAEs or adverse events associated with HTX-019 were reported. Also, no patients discontinued HTX-019 treatment, and none switched from HTX-019 to another NK-1 RA.

CONCLUSION

This is the first study to demonstrate that HTX-019 can be safely administered via IV push in patients with cancer receiving emetogenic chemotherapy while negating the need for fluid bags, which are scarce.

FUNDING

Heron Therapeutics, Inc., San Diego, CA, USA. Plain language summary available for this article.

Collapse

Boccia R, Geller RB, Clendeninn N, Ottoboni T. Hypersensitivity and infusion-site adverse events with intravenous fosaprepitant after anthracycline-containing chemotherapy: a retrospective study. Future Oncol 2019;15:297-303. [DOI: 10.2217/fon-2018-0662] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open

Navari RM. HTX-019: polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxis. Future Oncol 2018;15:241-255. [PMID: 30304952 DOI: 10.2217/fon-2018-0577] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open

Ottoboni T, Lauw M, Keller MR, Cravets M, Manhard K, Clendeninn N, Quart B. Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects. Future Oncol 2018;14:2849-2859. [PMID: 29873529 DOI: 10.2217/fon-2018-0311] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open

Schwartzberg LS, Navari RM. Safety of Polysorbate 80 in the Oncology Setting. Adv Ther 2018;35:754-767. [PMID: 29796927 PMCID: PMC6015121 DOI: 10.1007/s12325-018-0707-z] [Citation(s) in RCA: 109] [Impact Index Per Article: 18.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2018] [Indexed: 01/04/2023]

Chau E, Lundberg J, Phillips G, Berger M, Wesolowski R. Updated report on incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant. J Oncol Pharm Pract 2018;25:1053-1057. [DOI: 10.1177/1078155218769347] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]

Ottoboni T, Keller MR, Cravets M, Clendeninn N, Quart B. Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation. DRUG DESIGN DEVELOPMENT AND THERAPY 2018. [PMID: 29535504 PMCID: PMC5837372 DOI: 10.2147/dddt.s155875] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]

Abstract

Introduction

Fosaprepitant, an intravenous (IV) aprepitant prodrug for chemotherapy-induced nausea and vomiting prophylaxis, is associated with systemic and infusion-site reactions attributed in part to its surfactant, polysorbate 80. HTX-019 is an IV aprepitant formulation free of polysorbate 80 and other synthetic surfactants.

Materials and methods

This open-label, single-dose, randomized, two-way crossover bioequivalence study compared pharmacokinetics and safety of HTX-019 and fosaprepitant. Healthy subjects received single-dose HTX-019 (130 mg) or fosaprepitant (150 mg) IV over 30 min, with ≥7-day washout between doses. Blood samples were evaluated for pharmacokinetics and bioequivalence; safety evaluation included treatment-emergent adverse events (TEAEs) and serious adverse events. Ninety-seven of one hundred enrolled subjects completed the study.

Results

Baseline characteristics were comparable between treatment sequences. For HTX-019, mean (percent coefficient of variation) area under the curve (AUC) from time 0 to time of last measurable plasma concentration (AUC_0−t), AUC from time 0 to infinity (AUC_0−inf), and plasma concentration at 12 h (C_{12 h}) for HTX-019 were 43,729 h*ng/mL (32.7), 45,460 h*ng/mL (36.8), and 988.4 ng/mL (27.5), respectively; corresponding fosaprepitant values were 44,130 h*ng/mL (32.0), 46,163 h*ng/mL (36.6), and 1,022 ng/mL (28.5). Also, 90% CIs (94.186–101.354) were within bioequivalence bounds (80%–125%). Within 1 h following infusion start, one (1%) HTX-019 recipient reported one TEAE, while 20 (20%) fosaprepitant recipients reported 32 TEAEs. Dyspnea occurred in three fosaprepitant recipients (at <1 min in two subjects and at 18 min in one subject, considered study drug related) and one HTX-019 recipient (at 120 h, associated with a respiratory tract infection and considered not related to the study drug). No severe TEAEs, serious adverse events, or deaths occurred; all TEAEs resolved.

Conclusion

HTX-019 was bioequivalent to fosaprepitant and may provide a safer alternative to fosaprepitant for chemotherapy-induced nausea and vomiting prophylaxis.

Collapse

Gonçalves SC, Sanches SM, Bueno CT, Villela de Castro DL, Damascena A, Santos GRC. Incidence of Infusion Site Reactions in Peripheral Fosaprepitant Infusions. JOURNAL OF INFUSION NURSING 2017;40:380-383. [PMID: 29112587 DOI: 10.1097/nan.0000000000000252] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]

Lu Y, Hao C, He W, Tang C, Shao Z. Experimental research on preventing mechanical phlebitis arising from indwelling needles in intravenous therapy by external application of mirabilite. Exp Ther Med 2017;15:276-282. [PMID: 29250150 PMCID: PMC5729698 DOI: 10.3892/etm.2017.5347] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2017] [Accepted: 09/25/2017] [Indexed: 11/21/2022] Open

Abstract

Various types of complications arising from intravenous indwelling needles have become a challenge in clinical care. It is urgent to seek a simple and cost-effective method for prevention and treatment of phlebitis. We investigated the roles of mirabilite in preventing and treating phlebitis caused by intravenous indwelling needles and provide guidance for prevention and treatment of mechanical phlebitis caused by intravenous indwelling needles. A total of 57 healthy congeneric big-eared New Zealand rabbits were randomly divided into 3 groups: blank control, indwelling needle, and group with external application of mirabilite. The ear vein of each rabbit was punctured with an intravenous indwelling needle. The ear vein specimens were taken at 3, 5, and 7 days after indwelling. The hematoxylin and eosin stained pathological tissue sections of the ear veins of the rabbits in each group were observed. The expression levels of IL-1 and IL-6, and tumour necrosis factor-α (TNF-α) in the vascular tissue of the ear veins of the rabbits in each group were detected with the immunofluorescence method. In the blank control group, there was no inflammatory cellular infiltration and no proliferation of fibrous tissue around the vascular wall. With the increase of the indwelling time, proliferation of fibrous tissue in vascular wall, increased inflammatory cellular infiltration and organized thrombus in the vascular tissue occurred in the ear veins of the rabbits in the indwelling needle group and group with external application of mirabilite. Compared with the indwelling needle group, the group with external application of mirabilite had significantly decreased fibrous tissue in the vascular wall and significantly decreased inflammatory cellular infiltration. At the same point in indwelling time, the expression levels of IL-1, IL-6, and TNF-α in the indwelling needle and group with external application of mirabilite were significantly higher than that in the blank control group (P<0.05). The expression levels of IL-1, IL-6, and TNF-α in the group with external application of mirabilite were lower than that in the indwelling needle group (P<0.05). The expression levels of IL-1, IL-6, and TNF-α are positively correlated with the indwelling time within the same group at different points in time. In conclusion, external application of mirabilite can significantly decrease infiltration of venous inflammatory cells of the rabbit ear margin, proliferation of fibrous tissue and thrombosis in the vascular wall, significant decrease the expression levels of IL-1, IL-6, and TNF-α in the mechanical phlebitis caused by intravenous indwelling needles, and decrease the inflammatory responses of the ear veins of rabbits.

Collapse

Patel P, Leeder JS, Piquette‐Miller M, Dupuis LL. Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol 2017;83:2148-2162. [PMID: 28470980 PMCID: PMC5595939 DOI: 10.1111/bcp.13322] [Citation(s) in RCA: 54] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2017] [Revised: 04/12/2017] [Accepted: 04/21/2017] [Indexed: 12/12/2022] Open

Candelario N, Lu MLR. Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectives. Cancer Manag Res 2016;8:77-82. [PMID: 27382332 PMCID: PMC4922819 DOI: 10.2147/cmar.s93620] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open

Rapoport B, Chua D, Poma A, Arora S, Wang Y, Fein LE. Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). Support Care Cancer 2015;23:3281-8. [DOI: 10.1007/s00520-015-2738-1] [Citation(s) in RCA: 56] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2015] [Accepted: 04/06/2015] [Indexed: 11/24/2022]